Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL4144277 | 1.00 | LMNA (0.31) | LMNADPP4ADRA1AHTT | |
| Iodide SCHEMBL22495728 | 1.00 | LMNA (0.31) | LMNADPP4ADRA1AHTT | |
| SCHEMBL1298530 | 0.98 | LMNA (0.32) | LMNADPP4ADRA1AHTT | |
| SCHEMBL1298528 | 0.98 | LMNA (0.32) | LMNADPP4ADRA1AHTT | |
| SCHEMBL13696643 | 0.98 | LMNA (0.32) | LMNADPP4ADRA1AHTT | |
| SCHEMBL27361540 | 0.71 | — | — | |
| SCHEMBL20928355 | 0.71 | — | — | |
| SCHEMBL9913825 | 0.71 | — | — | |
| SCHEMBL19245862 | 0.70 | — | — | |
| SCHEMBL18351983 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | LMNA 4458/4885DPP4 1012/4885ADRA1A 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.